ProtoKinetix is a bio-technology company that provides medical researchers with a platform for enhancing cell survival and health, both in vitro and in vivo. At the heart of its technology is its patented anti-aging glycopeptide AAGP. This small molecule (580 Daltons) displays abilities in resolving challenges confronting medical researchers in such areas as regenerative medicine and as a therapy for diseases relating to tissue inflammation and oxidation stress. Because of its stability, small size and molecular makeup, it maintains its function in vivo without triggering the body's immune system. Further, it can function without toxic side effects common in treatments involving larger and less stable compounds.